Open Access. Powered by Scholars. Published by Universities.®

Pharmacoeconomics and Pharmaceutical Economics Commons

Open Access. Powered by Scholars. Published by Universities.®

108 Full-Text Articles 231 Authors 58,080 Downloads 45 Institutions

All Articles in Pharmacoeconomics and Pharmaceutical Economics

Faceted Search

108 full-text articles. Page 2 of 5.

Cost Effectiveness Analysis Of Enzalutamide, Abiraterone Plus Prednisone And Cabazitaxel Plus Predinsone For The Treatment Of Visceral Metastatic Castration Resistant Prostate Cancer (Mcrpc) After Docetaxel Therapy, Yazan K. Barqawi 2018 University of New Mexico

Cost Effectiveness Analysis Of Enzalutamide, Abiraterone Plus Prednisone And Cabazitaxel Plus Predinsone For The Treatment Of Visceral Metastatic Castration Resistant Prostate Cancer (Mcrpc) After Docetaxel Therapy, Yazan K. Barqawi

Pharmaceutical Sciences ETDs

Background: Prostate cancer is the second leading cause of death after lung cancer among men in the US. The America Cancer Society predicts 164,690 new cases and 29,430 prostate cancer deaths in 2018. Of those diagnosed with prostate cancer, about 10-20 % will develop castration-resistant prostate cancer (CRPC) within 5 years of diagnosis and 70 % of those cases will metastasize to mCRPC. In 2014, nearly US $13.4 billion was spent on prostate cancer in the US and expected to reach US $15.4 billion by 2020; making prostate cancer the fifth most costly cancer.

Objective: To conduct a ...


Will Removing Rebates Really Lower Drug List Prices?, Stephanie Tran 2018 University of Massachusetts Medical School

Will Removing Rebates Really Lower Drug List Prices?, Stephanie Tran

Commonwealth Medicine Publications

The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs calls for incentives to lower drug list prices, including removing rebates. Our clinical consultant Stephanie Tran continues our pharmacy blog series with an assessment of this potential change & its impacts.


Save The Pharmacy Piggy Bank: Managing Mega High-Cost Drugs, Richard K. Ogden Jr., Jerame Hill, Sam Abdelghany 2018 Children's Mercy Hospital

Save The Pharmacy Piggy Bank: Managing Mega High-Cost Drugs, Richard K. Ogden Jr., Jerame Hill, Sam Abdelghany

Pharmacy Presentations

No abstract provided.


Save The Pharmacy Piggy Bank: Managing Mega High-Cost Drugs, Richard K. Ogden Jr., Jerame Hill, Sam Abdelghany 2018 Children's Mercy Kansas City

Save The Pharmacy Piggy Bank: Managing Mega High-Cost Drugs, Richard K. Ogden Jr., Jerame Hill, Sam Abdelghany

Pharmacy Posters

No abstract provided.


Better Negotiations Between Payers And Manufacturers In An Effort To Reduce Drug Prices, Mckenzie Taylor 2018 University of Massachusetts Medical School

Better Negotiations Between Payers And Manufacturers In An Effort To Reduce Drug Prices, Mckenzie Taylor

Commonwealth Medicine Publications

Mckenzie Taylor continues our monthly conversation on the strategies presented in The Trump Administration Blueprint to Low Drug Prices and Reduce Out-of-Pocket Costs, discussing the ways new negotiations between payers and manufacturers are helping to reduce drug prices.


The Pharmaceutical Industry: A Pharmacy Student's Guide, Christian Egly, Yaman Kaakeh 2018 Purdue University

The Pharmaceutical Industry: A Pharmacy Student's Guide, Christian Egly, Yaman Kaakeh

Purdue Journal of Service-Learning and International Engagement

Christian Egly is a fourth-year (P4) pharmacy student in the Purdue University College of Pharmacy. During his years at Purdue, he worked in labs performing bench research in clinical pharmacology and biochemistry. He plans to work in the pharmaceutical industry after graduation. During his fourth year, he completed rotations in business development at Kashiv Pharma, LLC, and was hired there for an internship in 2017. In the article, Christian describes his personal experiences at Kashiv Pharma, LLC, and how industry can positively affect patient communities.


Cost-Effectiveness Analysis Of Enzalutamide, Abiraterone Acetate Plus Prednisone, Cabazitaxel Plus Prednisone For The Treatment Of Visceral Metastatic Castration Resistant Prostate Cancer (Mcrpc) After Docetaxel Therapy, Yazan K. Barqawi 2018 University of New Mexico

Cost-Effectiveness Analysis Of Enzalutamide, Abiraterone Acetate Plus Prednisone, Cabazitaxel Plus Prednisone For The Treatment Of Visceral Metastatic Castration Resistant Prostate Cancer (Mcrpc) After Docetaxel Therapy, Yazan K. Barqawi

Shared Knowledge Conference

Background: Prostate cancer is the second leading cause of death after lung cancer among men in the US. The America Cancer Society predicts 164,690 new cases and 29,430 prostate cancer deaths in 2018. In 2014, nearly US $13.4 billion was spent on prostate cancer in the US and expected to reach US $15.4 billion by 2020. Objective: To conduct a cost-effective analysis of visceral mCRPC therapies post-docetaxel failure from a US healthcare payer perspective utilizing life-time horizon Markov model. These medications received highest National Comprehensive Cancer Network guideline recommendation to treat visceral mCRPC post-docetaxel failure. Methods ...


How Can Improved Competition Lead To Lower Drug Prices?, Youkavet Samih 2018 University of Massachusetts Medical School

How Can Improved Competition Lead To Lower Drug Prices?, Youkavet Samih

Commonwealth Medicine Publications

In this installment of our blog series on "President Trump's Blueprint to Lower Drug Prices and Reduce Out-Of-Pocket Costs," our pharmacy expert Youkavet Samih discusses how creating drug competition drives down prices for consumers.


Cervical Ripening For Induction Of Labor, Deb Sepulveda, Michael G. Pinette, Heidi Morin, Colette Dumais, Sarah Austin, Hector Tarraza, Maria Tkacz, Zander Abbott 2018 Maine Medical Center

Cervical Ripening For Induction Of Labor, Deb Sepulveda, Michael G. Pinette, Heidi Morin, Colette Dumais, Sarah Austin, Hector Tarraza, Maria Tkacz, Zander Abbott

Maine Medical Center

Decrease in Cervidil use for cervical ripening by 20% of anticipated doses prior to Dec 1, 2018 (6 mos) , with a potential for cost savings = 40 doses x approx. $2000/dose = $80,000.


Improving The Management Of Nationwide Drug And Iv Bag Shortages, Inpatient Pharmacy, Supply Chain, Stephen Tyzik, Mark Parker, Suneela Nayak, Ruth Hanselman, Amy Sparks 2018 Maine Medical Center

Improving The Management Of Nationwide Drug And Iv Bag Shortages, Inpatient Pharmacy, Supply Chain, Stephen Tyzik, Mark Parker, Suneela Nayak, Ruth Hanselman, Amy Sparks

Operational Excellence

IMPROVING THE MANAGEMENT OF NATIONWIDE DRUG AND IV SHORTAGE

In September of 2017, Hurricane Maria struck the island of Puerto Rico where over 50 pharmaceutical factories had previously operated. The impact of this was felt not only in the drastic reduction of products that are produced on the island, but it also exacerbated the supply chain issues for key drugs nationwide.

The pharmacy department and supply chain in an academic tertiary care medical center did not have a consistent and reliable process for communication, planning and real-time updates. This resulted in a tremendous amount of wasted staff time at their ...


The Implementation Process For Pharmacogenomic Testing For Cancer-Targeted Therapies, Ann Chen Wu, Kathleen M. Mazor, Rachel Ceccarelli, Stephanie Loomer, Christine Y. Lu 2018 Harvard Medical School

The Implementation Process For Pharmacogenomic Testing For Cancer-Targeted Therapies, Ann Chen Wu, Kathleen M. Mazor, Rachel Ceccarelli, Stephanie Loomer, Christine Y. Lu

Open Access Publications by UMMS Authors

Recent advances in genomic medicine have led to the availability of genomic tests that have the potential to improve population health, yet the process for obtaining these tests and getting them reimbursed by insurers has not been described. The objective of this study was to describe the process of ordering pharmacogenomic tests by interviewing providers, patients, and laboratories about cancer-related pharmacogenomic tests. We interviewed patients who were prescribed, providers who prescribed medications that should be guided by pharmacogenomic testing, and individuals from diagnostic laboratories. A total of 10 providers, 16 patients, and eight diagnostic laboratories described logistical and insurance issues ...


A View Of The Drug Pricing Blueprint, Bonnie C. Greenwood 2018 University of Massachusetts Medical School

A View Of The Drug Pricing Blueprint, Bonnie C. Greenwood

Commonwealth Medicine Publications

Drug spend is predicted to experience the fastest annual growth between 2017-2026 compared to other health care goods and services.Contributing factors include increasing unit prices of branded and generic medications, growth of the specialty drug market, and greater numbers of people with access to prescription drug coverage. A recent analysis estimates total drug expenditures in 2016 to be $480 billion when accounting for gross profits of intermediaries in the distribution chain, such as wholesalers, pharmacy benefit managers (PBMs), and pharmacies. Certainly, the complexity of the drug distribution and reimbursement system and lack of pricing transparency can be viewed both ...


Evaluating Feasibility Of Blockchain Application For Dscsa Compliance, Tracie Scott, Armand L. Post, Johnny Quick, Sohail Rafiqi 2018 Southern Methodist University

Evaluating Feasibility Of Blockchain Application For Dscsa Compliance, Tracie Scott, Armand L. Post, Johnny Quick, Sohail Rafiqi

SMU Data Science Review

Abstract. We evaluated the feasibility of using a blockchain technology to create a traceability solution for pharmaceutical drugs that would promote compliance with recent legislation. Counterfeit and other illegitimate pharmaceutical drugs threaten patient safety, drug efficacy, and patient trust. The purpose of the Drug Supply Chain Security Act (DSCSA) is to greatly reduce distribution of illegitimate drugs by requiring all pharmaceuticals to be serialized and traceable from the manufacturer through the supply chain to the dispenser. A software application to serialize and track pharmaceuticals must overcome numerous obstacles. In particular, the solution must provide a high degree of trust while ...


Radical Social Ecology As Deep Pragmatism: A Call To The Abolition Of Systemic Dissonance And The Minimization Of Entropic Chaos, Arielle Brender 2018 Fordham University

Radical Social Ecology As Deep Pragmatism: A Call To The Abolition Of Systemic Dissonance And The Minimization Of Entropic Chaos, Arielle Brender

Student Theses 2015-Present

This paper aims to shed light on the dissonance caused by the superimposition of Dominant Human Systems on Natural Systems. I highlight the synthetic nature of Dominant Human Systems as egoic and linguistic phenomenon manufactured by a mere portion of the human population, which renders them inherently oppressive unto peoples and landscapes whose wisdom were barred from the design process. In pursuing a radical pragmatic approach to mending the simultaneous oppression and destruction of the human being and the earth, I highlight the necessity of minimizing entropic chaos caused by excess energy expenditure, an essential feature of systems that aim ...


A Comparison Of The Costs Associated With The Administration Of Select High-Cost Infused Medications In Three Sites Of Care For A State Medicaid Population, Sage Bagwell, Pavel Lavitas, Thomas C. Pomfret, Bonnie C. Greenwood, Nicole M. Trask, Stephanie Tran, Nancy L. Schiff, Tasmina Hydery, Patricia Leto, Mylissa K. Price, Caroline J. Alper, Kimberly J. Lenz, Paul L. Jeffrey 2018 University of Massachusetts Medical School

A Comparison Of The Costs Associated With The Administration Of Select High-Cost Infused Medications In Three Sites Of Care For A State Medicaid Population, Sage Bagwell, Pavel Lavitas, Thomas C. Pomfret, Bonnie C. Greenwood, Nicole M. Trask, Stephanie Tran, Nancy L. Schiff, Tasmina Hydery, Patricia Leto, Mylissa K. Price, Caroline J. Alper, Kimberly J. Lenz, Paul L. Jeffrey

Commonwealth Medicine Publications

This poster evaluates the financial impact of high-cost infused medications across three site of care programs. Site of care programs help payers save money on specialty drug spend by shifting utilization on high costs infused medications to less costly sites of administration. The objective of this project was to evaluate the costs associated with the administration of select high-cost infused medications in site of care programs in Massachusetts Medicaid populations. Research was done through retrospective analysis that included pharmacy and medical claims data for select high cost infused medications between April 1, 2017 - September 20, 2017.

This presentation was given ...


Effect Of Study Design On Sample Size In Studies Intended To Evaluate Bioequivalence Of Inhaled Short-Acting Β-Agonist Formulations, Yaohui Zeng, Sachinkumar Singh, Kai Wang, Richard C Ahrens 2018 University of Iowa

Effect Of Study Design On Sample Size In Studies Intended To Evaluate Bioequivalence Of Inhaled Short-Acting Β-Agonist Formulations, Yaohui Zeng, Sachinkumar Singh, Kai Wang, Richard C Ahrens

Stead Family Department of Pediatrics Publications

Pharmacodynamic studies that use methacholine challenge to assess bioequivalence of generic and innovator albuterol formulations are generally designed per published Food and Drug Administration guidance, with 3 reference doses and 1 test dose (3-by-1 design). These studies are challenging and expensive to conduct, typically requiring large sample sizes. We proposed 14 modified study designs as alternatives to the Food and Drug Administration-recommended 3-by-1 design, hypothesizing that adding reference and/or test doses would reduce sample size and cost. We used Monte Carlo simulation to estimate sample size. Simulation inputs were selected based on published studies and our own experience with ...


A Budget Impact Model For Two Investigational Agents For The Treatment Of Nonalcoholic Steatohepatitis, Nicole M. Trask, Pavel Lavitas, Vincent Palumbo 2018 University of Massachusetts Medical School

A Budget Impact Model For Two Investigational Agents For The Treatment Of Nonalcoholic Steatohepatitis, Nicole M. Trask, Pavel Lavitas, Vincent Palumbo

Commonwealth Medicine Publications

Statistics show approximately 15 million Americans suffer from NASH, a nonalcoholic fatty liver disease that is projected to become the most common reason for liver transplantation. There are no FDA approved therapies for NASH, so doctors are forced to treat patients with off-label medications while keeping an eye out for breakthroughs in medication development.

Two novel therapies, obeticholic acid and elafibranor, are currently in Phase III trials. If they receive FDA approval, interest will be high as they will be the first treatments specifically labeled for NASH. We detail a budget impact model for a sample state Medicaid plan in ...


Prescription Drug Monitoring Programs And Opioid Poisoning: Evaluating The Impact Of Prescriber Use Mandates On Prescription Opioid Poisoning Emergency Department Visits, Sarah Almanie 2018 Virginia Commonwealth University

Prescription Drug Monitoring Programs And Opioid Poisoning: Evaluating The Impact Of Prescriber Use Mandates On Prescription Opioid Poisoning Emergency Department Visits, Sarah Almanie

Theses and Dissertations

Introduction: Prescription drug monitoring programs (PDMPs) are one strategy established to curb the prescription opioid abuse epidemic. Prescriber use mandates has emerged as a promising practice to increase PDMPs impact on prescription opioid abuse; however, evidence of its effectiveness has not yet been established. Kentucky was the first state to implement comprehensive prescriber use mandates in July 2012.

Objective: To assess the relationship between prescriber use mandates policy and emergency department (ED) visits related to prescription opioid poisoning among adults in Kentucky and

North Carolina. Secondary aim: to evaluate the economic impact of prescriber use mandates in Kentucky.

Methods: A ...


Economic Burden Of Renal Cell Carcinoma (Rcc) And Treatment Patterns, Overall Survival And Healthcare Costs Among Older Metastatic Rcc Patients, Hrishikesh P. Kale 2018 Virginia Commonwealth University

Economic Burden Of Renal Cell Carcinoma (Rcc) And Treatment Patterns, Overall Survival And Healthcare Costs Among Older Metastatic Rcc Patients, Hrishikesh P. Kale

Theses and Dissertations

Background

Renal cell carcinoma (RCC) is the most common type of kidney cancer. Patients diagnosed with metastatic RCC (mRCC) have shorter overall survival compared to those diagnosed at earlier stages. Several targeted therapies, which cost from $7,000 - $16,000 per month have been approved since 2005 to treat mRCC. In addition, there is a growing interest in the use of cytoreductive nephrectomy (CN) with targeted therapies among mRCC patients. However, little is known regarding the economic burden of RCC and role of CN and prescribing patterns of targeted therapies among older mRCC patients.

Objectives

1) To assess the economic ...


Decreasing Unnecessary Pharmacy Cost In The Cath Lab, Scott M. Scepaniak, Kristi Patterson 2018 St. Cloud Hospital, CentraCare Health

Decreasing Unnecessary Pharmacy Cost In The Cath Lab, Scott M. Scepaniak, Kristi Patterson

Nursing Posters

AngioMax is a single dose heparin alternative introduced in 2002 that is used in cardiac patients undergoing percutaneous intervention (PCI). Bivalirudin costs $377 per dose; heparin is less than $15 per dose. Noting practice variations, the Cath Lab set out to eliminate unnecessary pharmacy cost for PCI patients by:

  • Using current literature to inform clinical care
  • Standardizing practice
  • Using data to track and guide implementation


Digital Commons powered by bepress